| Property | Value |
|
overview
|
Mark Applebaum, MD, is an expert in pediatric cancers and blood diseases. He has a special interest in the treatment of neuroblastoma, sarcomas and solid tumors.
Dr. Applebaum is a translational physician-scientist working on harnessing genomics and “big data” to advance treatments for children with neuroblastoma. He bridges the fields of epigenetics, genomics, and cancer biology to identify idenitfy novel risk classifiers and therapeutic targets.
Dr. Applebaum focuses his research on how specific epigenetic marks can identify patients with aggressive neuroblastoma that may benefit from alternatives to standard therapy. His laboratory is also identifying how the low-oxygen environment of tumors makes cancer cells more resistant to standard therapies by inducing changes in these same epigenetic marks. Identifying the genes and cellular pathways responsible for these changes may ultimately open new avenues for novel therapeutic options.
Dr. Applebaum's research is supported by the National Cancer Institute and the University of Chicago Cancer Center Auxiliary Board. He has received funding from the Conquer Cancer Foundation, Cancer Research Foundation, and the Bear Necessities Foundation. He is the recipient of numerous awards from the American Society of Clinical Oncology, the American Association of Cancer Researchers, and the Advances in Neuroblastoma Research Association.
|